help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on November 11, 2005, doi:10.1165/rcmb.2005-0286OC

Am. J. Respir. Cell Mol. Biol., Volume 34, Number 3, March 2006, 355-363

A more recent version of this article appeared on March 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0286OCv1
34/3/355    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grubb, B. R
Right arrow Articles by Boucher, R. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grubb, B. R
Right arrow Articles by Boucher, R. C

Submitted on July 25, 2005
Revised on November 11, 2005

SERCA Pump Inhibitors Do Not Correct Biosynthetic Arrest of {Delta}F508CFTR in Cystic Fibrosis

Barbara R Grubb1*, Sherif E Gabriel1, April Mengos2, Martina Gentzsch2, Scott H Randell1, Anna M Van Heeckeren3, Michael R Knowles1, Mitchell L Drumm3, John R Riordan2, and Richard C Boucher1

1 CF/Pulmonary Research and Treatment Center, The University of North Carolina, Chapel Hill, NC, USA, 2 Department of Cell Biology and Genetics, Mayo Clinic College of Medicine, Scottsdale, AZ, USA, 3 Department of Pediatric Pulmonology, Case Western Reserve University, Cleveland, OH, USA

* To whom correspondence should be addressed. E-mail: bgrubb{at}med.unc.edu.

Deletion of phenylalanine 508 ({Delta}F508) accounts for nearly 70% of all mutations that occur in the cystic fibrosis transmembrane conductance regulator (CFTR). The {Delta}F508 mutation is a class II processing mutation that results in very little or no mature CFTR protein reaching the apical membrane and thus no cAMP-mediated Cl- conductance. Therapeutic strategies have been developed to enhance processing of the defective {Delta}F508-CFTR molecule so that a functional cAMP-regulated Cl- channel targets to the apical membrane. SERCA inhibitors, curcumin and thapsigargin, have been reported to effectively correct the CF ion transport defects observed in the {Delta}F508 CF mice. We investigated the effect of these compounds in human airway epithelial cells to determine if they could induce {Delta}F508-CFTR maturation, and Cl- secretion. We also used Baby Hamster Kidney cells, heterologously expressing {Delta}F508-CFTR, to determine if SERCA inhibitors could interfere with the interaction between calnexin and CFTR and thereby correct the {Delta}F508-CFTR misfolding defect. Finally, at the whole animal level, we tested the ability of curcumin and thapsigargin to i) induce Cl- secretion and reduce hyperabsorption of Na+ in the nasal epithelia of the {Delta}F508 mouse in vivo, and ii) induce Cl- secretion in intestine (jejunum and distal colon) and the gallbladder of the {Delta}F508 CF mouse. We conclude that curcumin and thapsigargin failed to induce maturation of {Delta}F508-CFTR, or induce Cl- secretion, as measured by biochemical and electrophysiological techniques in a variety of model systems ranging from cultured cells to in vivo studies.




This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
A. Sobolewski, N. Rudarakanchana, P. D. Upton, J. Yang, T. K. Crilley, R. C. Trembath, and N. W. Morrell
Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue
Hum. Mol. Genet., October 15, 2008; 17(20): 3180 - 3190.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
X.-b. Chang, A. Mengos, Y.-x. Hou, L. Cui, T. J. Jensen, A. Aleksandrov, J. R. Riordan, and M. Gentzsch
Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator
J. Cell Sci., September 1, 2008; 121(17): 2814 - 2823.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. Vogt, J. Bustamante, A. Chapgier, J. Feinberg, S. Boisson Dupuis, C. Picard, N. Mahlaoui, L. Gineau, A. Alcais, C. Lamaze, et al.
Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation
J. Exp. Med., August 4, 2008; 205(8): 1729 - 1737.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. S. Ostedgaard, C. S. Rogers, Q. Dong, C. O. Randak, D. W. Vermeer, T. Rokhlina, P. H. Karp, and M. J. Welsh
Processing and function of CFTR-{Delta}F508 are species-dependent
PNAS, September 25, 2007; 104(39): 15370 - 15375.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. Guilbault, Z. Saeed, G. P. Downey, and D. Radzioch
Cystic Fibrosis Mouse Models
Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 1 - 7.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2005 American Thoracic Society. 		  ATS Best of the Web